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Abstract 
 
For six decades, the principal mode of action of antidepressant drugs is the inhibition of 
monoamine re-uptake from the synaptic cleft. Tricyclic antidepressants, selective serotonin 
re-uptake inhibitors (SSRIs) and the new generation of dual antidepressants all exert their 
antidepressant effects by this mechanism. In the early days of the monoaminergic era, other 
intents have been made to ameliorate symptoms of depression by pharmacological means. 
The gamma-aminobutyric acid (GABA) system was and possibly still is one of the main 
alternative drug targets. Gammahydroxybutyrate (GHB) was developed as an orally active 
GABA analogue. It was tested in animal models of depression and human studies. The 
effects on sleep, agitation, anhedonia and depression were promising. But the rise of 
benzodiazepines and tricyclic antidepressants brought GHB out of scope of possible 
treatment alternatives. GHB is a GABAB and GHB receptor agonist with a unique spectrum of 
behavioral, neuroendocrine and sleep effects, and improves daytime sleepiness in various 
disorders such as narcolepsy, Parkinson's disease and fibromyalgia. Although it was banned 
from the US-market end of the 1990-ies because of its abuse and overdose potential, it later 
was approved for the treatment of narcolepsy. New research methods and an extended view 
on other neurotransmitter systems as possible treatment targets of antidepressant treatment 
brought GHB back to the scene. This article discusses the unique neurobiological effects of 
GHB, its misuse potential and possible role as a model substance for the development of 
novel pharmacological treatment strategies in depressive disorders. 
 
 3
Introduction 
 
Gammahydroxybutyrate (GHB) was first synthesized by Henri Laborit in 1960, who aimed to 
create an orally active GABA analogue (Laborit et al., 1960). The sedating and narcotic 
effects of the compound led to its first use in anaesthesia and later in psychiatry (Langlois et 
al., 1960). Early studies reported anxiolytic and antidepressant effects of GHB in psychiatric 
patients. GHB was well tolerated in these patients, dizziness and nausea being the most 
limiting adverse effects (Danon-Boileau et al., 1962; Rinaldi et al., 1967). Its unique effects 
on sleep parameters were recognized early on. GHB seemed to induce a close-to-
physiological sleep pattern with an increase in slow wave sleep (SWS) in humans (Mamelak 
et al., 1973). As benzodiazepines and tricyclic antidepressants were increasingly being 
prescribed, GHB was mainly used and studied in basic research. In the 1980ies GHB was 
available on the US market as a food supplement. It was abused by bodybuilders because of 
its stimulating effects on growth hormone release and thus its suspected anabolic potency. 
The US Food and Drug Administration (FDA) banned the drug in 1990 after cases of 
intoxication had occurred. As the abuse of the drug went on, the US government put it under 
narcotics law (Schedule I). However, GHB was approved for the treatment of narcolepsy with 
cataplexy in the US in 2002 and in Europe in 2005 (Carter et al., 2009). Furthermore, in Italy 
GHB is used and extensively studied in the treatment of alcohol addiction and craving (for 
review see Addolorato et al., 2009; and Leone et al., 2010). 
 
- Figure 1 about here - 
 
The contemporary focus on biological markers of depression as indicators of the treatment 
response and as targets of antidepressant therapy, has led to new interest in GABAergic 
substances and, thus, GHB (Mamelak, 2009). 
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Neuropharmacology of GHB 
 
GHB is an endogenous short fatty acid and a GABA metabolite that is present mainly in the 
hypothalamus and the basal ganglia in the mammal brain (Bessman and Fishbein, 1963; 
Snead and Morley, 1981). However, the highest concentrations can be found in peripheral 
body tissues such as the kidneys and brown fat (Nelson et al., 1981). The cerebral 
concentrations of GHB are approximately 0.1% of the concentrations of GABA (Maitre, 
1997). 
 
GHB has been described as an endogenous neurotransmitter due to the presence of specific 
G-protein coupled high and low affinity receptors (Kd1 = 30-580 nmol/l and Kd2 = 2.3-16 
μmol/l) and the specificity of the GHB antagonist NCS-382 (Benavides et al., 1982; Schmidt 
et al., 1991; Snead, 2000). Although various effects on several neurotransmitter systems 
have been reported, the precise physiological function of GHB remains a matter of debate 
(Wong et al., 2004; Crunelli et al., 2006; Andresen et al., 2011). Protective functions have 
been postulated, as GHB was shown to reduce the harmful effects of hypoxia and oxidative 
stress on various tissues in vitro and in vivo (e.g. heart, skeletal muscle, pancreatic β cells, 
lung, liver, gut, kidney and brain) (for review see Mamelak, 2007). However, later studies 
also showed induction of oxidative stress by GHB and its precursors in cerebral cortex of rats 
(Sgaravatti et al., 2007; 2009). 
 
GHB is orally active and rapidly absorbed, while bioavailability is only about 25% (Palatini et 
al., 1993). Dose administration after high-fat meals significantly reduces bioavailability of the 
drug (Borgen et al., 2003). GHB shows nonlinear pharmacokinetics. Peak plasma 
concentrations are reached within 20 to 50 minutes, correlating with subjective effects, while 
plasma half-life is about 30 to 40 minutes (Ferrara et al., 1992; Scharf et al., 1998; Borgen et 
al., 2004; Brenneisen et al., 2004; Abanades et al., 2006). Endogenous and exogenous GHB 
is rapidly and completely converted into CO2 and H2O through the tricarboxylic acid cycle 
 5
(Krebs cycle) (Maitre, 1997). Excretion happens through urine, breath and oral fluids 
(Brenneisen et al., 2004). 
 
Presumably, exogenous supraphysiological concentrations of GHB produce qualitatively 
different neuronal actions than those produced by endogenous GHB concentrations. Despite 
its high affinity to GHB receptors, most of its effects are mediated by an agonist action at 
GABAB receptors after exogenous application (Engberg and Nissbrandt, 1993). GABAB 
antagonists reverse and GABAB agonists mimic core effects of GHB on both the neuronal 
and behavioral level (Engberg and Nissbrandt, 1993; Kaupmann et al., 2003). However, the 
effects of GHB and the specific GABAB agonist baclofen can be differentiated experimentally 
(Mathivet et al., 1997; Wong et al., 2004). Thus, high concentrations of GHB might act on the 
high affinity GHB receptor and on the GABAB receptor, respectively.  
GHB was reported to increase dopamine and norepinephrine levels in a biphasic mode. First, 
the release of both neurotransmitters is inhibited, which leads to a neuronal accumulation. 
Then, the release of the accumulated dopamine and norepinephrine is stimulated, resulting 
in an increased temporary output of these neurotransmitters (Hechler et al., 1991; Maitre, 
1997; Pardi and Black, 2006). Moreover, an increase in serotonin synthesis and metabolism 
has been shown (Gobaille et al., 2002; Szabo et al., 2004) Although some effects of GHB 
can be antagonized by naloxone, thus indicating a certain opioidergic effect of the drug, no 
direct stimulation of mu, delta and kappa receptors could be shown (Hechler et al., 1991; 
Feigenbaum and Howard, 1996; Feigenbaum and Simantov, 1996). Furthermore, the 
cholinergic system is affected by GHB (Volpi et al., 2000), as well as the synthesis and 
release of hormones such as neurosteroids, growth hormone and cortisol, as described in 
detail below. 
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Subjective effects, medical use and abuse 
 
In the literature there is a relatively small but growing body of work investigating the 
subjective effects of GHB intoxication and the reasons underlying its illicit use. The subjective 
effects of GHB constitute a continuum between relaxation, increased social interaction, 
euphoria and increased well-being in lower doses (10 mg/kg) up to profound sedation and 
deep sleep in higher doses (30-50 mg/kg) (Delay et al., 1965; Rosen et al., 1997; Iten et al., 
2000; Barker et al., 2007). Doses over 50 mg/kg may cause coma and respiratory 
depression (Metcalf et al., 1966). Emergency ward patients with severe coma (Glasgow 
Coma Scale [GCS] 3-8) showed GHB serum levels that ranged from 72 to 430 mg/l. They 
abruptly regained consciousness after levels fell under 75 to 150 mg/l (Sporer et al., 2003; 
Van Sassenbroeck et al., 2007). Illicit GHB users describe its subjective effects as 
comparable to both alcohol and methylenedioxymethamphetamine (MDMA, “ecstasy”), with 
disinhibition, drowsiness, euphoria, and enhancing sensuality and empathogenesis. This is 
the reason why it was called “liquid ecstasy” in the club scene (Galloway et al., 2000). In an 
online survey (n = 189) the most frequently reported reasons for GHB use were for recreation 
purposes (18.3%), to enhance sex (18.3%), to be sociable (13.1%), and to explore altered 
states of consciousness (13.1%) (Sumnall et al., 2008). These data confirm previous studies 
concerning the motivations of illicit GHB use (Miotto et al., 2001; Degenhardt et al., 2002; 
Barker et al., 2007). The influence of GHB on sex is a popular theme throughout consumers 
of the drug. Many aspects of sexuality are said to be enhanced, such as sexual desire, 
arousal, and activity. A qualitative focus group study using structured interviews and 
questionnaires including 51 GHB users could confirm these anecdotal reports (Barker et al., 
2007).  
 
Sodium oxybate is the international drug name for the sodium salt of GHB. In research the 
terms are used synonymously. In numerous international multicenter trials, GHB has been 
shown to be an unparalleled treatment for the complex of narcolepsy symptoms: sleepiness, 
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sleep fragmentation and cataplexy (Xyrem-US, 2002; Xyrem-International, 2005). GHB oral 
solution (no tablet form available) is merchandized as Xyrem® in the U.S., Canada and 
Europe (incl. Switzerland). In these countries it is the first line treatment for excessive 
daytime sleepiness and cataplexy in patients with narcolepsy. GHB is approved in Germany 
as an anaesthetic, Somsanit® and is approved in Austria and Italy for the treatment of 
alcohol withdrawal as Alcover®, while it is also used off-label for opiate withdrawal 
(Gallimberti et al., 1994). 
Beneficial therapeutic effects in schizophrenia (Kantrowitz et al., 2009), posttraumatic stress 
disorder (Schwartz, 2007), affective disorders (Berner, 2008; Mamelak, 2009), excessive 
daytime sleepiness in fibromyalgia (Scharf et al., 2003) as well as in Parkinson’s disease 
(Ondo et al., 2008) have also repeatedly been reported. GHB is a robust enhancer of slow 
wave sleep in patients with sleep disorders with excessive daytime sleepiness and in healthy 
subjects (Van Cauter et al., 1997). Finally, GHB was shown to have a favourable safety 
profile both in therapeutic and experimental settings (Kantrowitz et al., 2009; Leone et al., 
2010).  
 
In a medical or scientific context, the risk of acute toxicity is low. Multicenter studies and post 
marketing surveillance for GHB (Xyrem) suggested a very low incidence of unexpected side 
effects even in long term use (Xyrem-US, 2002; Xyrem-International, 2005; Wang et al., 
2009). In addition to the regular spontaneous adverse event reporting system, a distribution 
and post-marketing surveillance system called Xyrem Success Program was created and a 
Post-Marketing Evaluation Program (PMEP) was implemented to guarantee the safe use of 
the drug (Fuller et al., 2004). Between 2002 and 2008 approximately 26.000 patients 
worldwide were treated with Xyrem, and approximately 600.000 bottles of the drug were 
distributed. The most frequently reported adverse events were nausea (2.2%), insomnia 
(1.4%), headache (1.4%), dizziness (1.3%) and vomiting (1.0%). Five incidents (0.0009%) of 
diversion of Xyrem bottles were reported (Wang et al., 2009).  Cases of development of 
addiction and deaths related to Xyrem treatment are discussed below. Residual toxicity of 
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GHB is very small as it is rapidly metabolized to CO2 and H2O as described above. 
Regarding the often supposed concern about the potential addictive effect of GHB (Galloway 
et al., 1997; Nicholson and Balster, 2001), animal studies showed a relatively low reinforcing 
effect compared to barbiturates and benzodiazepines. GHB and its precursors 1,4-butanediol 
(BDL) and gamma-butyrolactone (GBL) were not able to substitute for pentobarbital, 
methohexital, midazolam, diazepam or flumazenil in rhesus monkeys. Self-administration 
was lower than with these substances and the total maintained self-administration was 
marginally above saline levels (Woolverton et al., 1999; McMahon et al., 2003). In humans, a 
clear differentiation has to be made between illicit uncontrolled and medically supervised use 
of the substance. GHB is abused by a small percentage of the population (< 1%) as a 
recreational drug in a home setting or as a "club drug" (Sumnall et al., 2008). Unlike certain 
media reports suggested, the major type of GHB consumer was shown to be well-educated, 
financially secure and fully employed, living a stable, middle-class urban life (Degenhardt et 
al., 2002; Barker et al., 2007). In humans, the abuse liability was shown to be comparable to 
the benzodiazepine flunitrazepam (Abanades et al., 2007) and intermediate between 
triazolam and pentobarbital (Carter et al., 2006). GHB withdrawal after chronic and heavy 
use often may be accompanied by severe complications such as hypertonia and delirium and 
requires high doses of medication such benzodiazepines, antihypertensives and 
antipsychotics. Intensive care treatment comparable to alcohol or benzodiazepine withdrawal 
may be necessary (van Noorden et al., 2009). After abrupt discontinuation of GHB in patients 
with narcolepsy, 17% developed symptoms such as anxiety, dizziness, insomnia, and 
somnolence. Most of the symptoms were interpreted as recurring narcoleptic symptoms or 
mild withdrawal symptoms. Therefore, it is suggested to slowly taper off the drug if it is 
intended to be stopped (Xyrem-US, 2003). 
 
Cases of physical dependence have been reported in recreational illicit GHB users, but exact 
statistical analysis remains difficult as the estimated number of unreported non-dependent 
users is not known. Consequently, the risk for developing an addiction after regular illicit 
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GHB use shows high variations in the according studies. While 4% of GHB users presented 
addiction to GHB in an Australian sample with 76 subjects, in another study with a small 
sample size of 41 subjects, 9 of them (21%) reported to be physically dependent on the drug. 
In both studies, most GHB dependent subjects had histories of polydrug abuse including 
MDMA, cannabis, cocaine, and methamphetamine (Miotto et al., 2001; Degenhardt et al., 
2002; Carter et al., 2009). Compared to this, risk of substance dependency or withdrawal 
syndrome after the use of therapeutically applied GHB is low. In a post-marketing 
surveillance study, one case for every 3300 to 6500 patients treated, or approximately 0.031 
to 0.015 %, developed an addiction that fulfilled the DSM-IV criteria (Wang et al., 2009). 
Moreover, marked differences in patterns of use and dosing of GHB may be found in medical 
and illicit use. While GHB is given in doses of 4.5 to 9 g in two doses at night in a medical 
context, illicit use occurs with frequent dosing of 5 to 30 g GHB throughout day and night 
(Barker et al., 2007; Craig et al., 2000; Degenhardt et al., 2003; Miotto et al., 2001; Sumnall 
et al., 2008; Wojtowicz et al., 2008). 
 
As the therapeutic dose range of GHB is quite narrow, overdoses and the combination with 
central nervous system (CNS) depressants such as alcohol produce serious risks. Rapid loss 
of consciousness with coma necessitating intubation and intensive care is the most dreaded 
adverse effect of an acute GHB intoxication. Although cases of GHB-related death were 
reported from most of the countries where the drug is used illicitly, the relative and total 
numbers of fatal cases appear small (Andresen et al., 2008; Munir et al., 2008). In a Swedish 
sample of 23 deaths after GHB overdose, which occurred between the years 2000 and 2007, 
a coingestion of other substances or alcohol was found in 91% (Knudsen et al., 2010). 
Another case series of 226 GHB associated deaths, which occurred between 1995 and 2005 
in the USA, Canada and the UK, showed absence of co-intoxicants in only 35% of the 
subjects (Zvosec et al., 2010). Of 1.419 drug related deaths in the UK in 2009, 6 (0.4%) were 
due to GHB alone and 15 (1%) due to GHB in combination with other drugs. In comparison, 
Alcohol was implicated in 447 (31.5%) and Heroin in 689 (49.2%) cases of drug related 
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death (Ghodse et al., 2010). One problem of interpreting post mortem GHB concentrations in 
blood and urine is the endogenous production of GHB, which can lead to false positive 
effects. Blood concentrations less then 30 mg/l and urine concentrations of less then 20 mg/l 
are suspected to be due to endogenous release of GHB. Anyway, post-mortem GHB 
concentrations up to 197 mg/l could be detected in cases without previous ingestions of the 
drug (Elliot, 2001; Elliott, 2004). These concentrations overlap with the post mortem serum 
levels of GHB-related deaths, which showed a range between 18 to 4400 mg/l (Knudsen et 
al., 2010; Zvosec et al., 2010). Although most GHB fatalities happened in cases of illicit use, 
four deaths after medical use were also reported (Akins et al., 2009; Zvosec et al., 2009).  
 
Taken animal and human data together, the addictive potential of illicitly used GHB is 
comparable to alcohol and benzodiazepines and needs to be taken seriously (Gonzalez and 
Nutt, 2005). In contrast, the cumulative post marketing and clinical experience indicates a 
very low risk of abuse of therapeutically applied GHB (Wedin et al., 2006; Kantrowitz et al., 
2009).  
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GABAB receptors and GHB in depression: 
animal and human studies   
 
The GABAergic system is the principal mediator of neuronal inhibition in the brain. 
Dysfunction of GABA neurotransmission has been proposed to play an important role in 
psychiatric disorders, including anxiety and depression (Kalueff and Nutt, 2007). While the 
link between GABA and anxiety is clearly established, the importance of GABAergic 
dysfunction in the aetiology and course of depression remains unclear. Animal studies 
showed that alterations of GABAB receptor function cause antidepressant-like behaviour 
(Cryan and Slattery, 2010). Some human studies indicate a beneficial effect of the GABAB 
agonist baclofen on depression symptoms (Krupitsky et al., 1993; Drake et al., 2003). 
Baclofen is further known to impair cognition by its sedative effect and to increase 
concentrations of both growth hormone (Cavagnini et al., 1977) and cortisol (Morosini et al., 
1980).  
 
Shortly after the discovery of GHB by Laborit in 1960, the drug was tested in clinical 
psychiatric populations. As GHB was meant to induce an almost physiological or natural 
sleep, it was applied to sedate patients with alcohol withdrawal syndrome and severe anxiety 
states. The favourite mode of application was i.v. or s.c., using doses between 2 to 5 g 
(Laborit et al., 1960; Langlois et al., 1960; Danon-Boileau et al., 1962). Also GBL, a 
precursor of GHB, was tested successfully in the treatment of alcohol withdrawal and 
psychotic states with agitation and anxiety (Benda et al., 1960). In a study with 15 psychiatric 
patients, mainly with depression and anxiety disorders, GHB application of 2 g i.v. three 
times daily lead to a good clinical improvement of most patients. The drug was given over a 
period of 4 to 15 days. Reported general effects were relaxation and euphoria instantly after 
administration and a normalization of affective symptoms in the course of the treatment. A 
marked improvement of interpersonal contact was the main behavioral change, resulting in 
an amelioration of the psychotherapeutic alliance. The limiting side effect was nausea with 
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vomiting, which led to discontinuation of the treatment in three cases (Danon-Boileau et al., 
1962). In another study, GHB was used either to induce sleep therapy (n = 10) or as 
tranquilizing agent to facilitate psychotherapy (n = 20) in patients with various psychiatric 
disorders (schizophrenia, depression, anxiety) (Ducouedic et al., 1964). The drug showed a 
high efficacy for both treatments. Sleep induction was reliable and safe and patients woke up 
easily without being hung over. A robust reduction of anxiety could be achieved in wake 
patients with three injections of GHB daily. The authors underlined the prosocial and contact 
facilitating effects of the drug, as they enabled psychotherapeutic dialogs in patients 
previously inhibited by their severe psychopathology. 
The first systematic though not placebo-controlled study with GHB in patients with 
depressive disorder was performed by Rinaldi and colleagues (1967). Single evening i.v. 
injections of 4 g GHB repeated for 3 to 12 days were used as tentative therapy in a group of 
30 female depressed patients. Symptoms of depression were measured by the Wechsler 
Depression Rating Scale (W-DRS) and the Zung Self-rating Depression Scale (Z-SDS). The 
best response was seen in core depression symptoms such as depressed mood, insomnia, 
loss of appetite and fatigue. After a sudden partial improvement of symptoms during the first 
24 h, complete remission was achieved at the end of treatment in 24 patients after only 12 
days (Rinaldi et al., 1967).   
 
In animal models of depression, which were sensitive to antidepressive effects of other 
pharmacological agents, GHB and its analogues produced antidepressant-like changes in 
behaviour and neurotransmitter release (Davies, 1978; Zerbib et al., 1992). GBL showed a 
biphasic behavioral effect in rats. Initially, locomotor activity of the animals was reduced after 
intraperitoneal injections of 100 and 200 mg/kg of the drug. This reduction was then followed 
by a period of hyperactivity. This increase of activity was probably due to a release of 
dopamine, as the indirect dopamine receptor agonist benztropine (25 mg/kg) potentiated, 
while the dopamine D2-receptor antagonist α-flupenthixol (50 µg/kg) blocked the effect 
(Davies, 1978). This biphasic effect on the neuronal dopaminergic system was hypothesized 
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to be a neurobiological correlate to the initially sedative and then euphoric/mood augmenting 
properties of GHB in depressed patients. These results were confirmed by Zerbib and 
colleagues (1992) in mice after acute and chronic application of 2 mmol/kg GHB i.p.. 
Additionally, striatal dopamine concentrations and immobility in the behavioral despair test 
(BDT) were assessed. A potential antidepressant effect could be shown, which was similar to 
the effect of imipramine but not to the effects of antipsychotics or anxiolytics (Zerbib et al., 
1992). 
 
Taken animal and limited human data together, GHB appears as a compound with unique 
pharmacological properties and potential antidepressant effects. In the first place, GHB acts 
as a tranquilizing agent, showing dose-dependent effects ranging from increase of sociability 
and anxiolysis to sleep induction. Apart of these, mainly GABAergic mechanisms, secondary 
effects on the monoaminergic systems (serotonin, norepinephrine and dopamine) might play 
a role in the antidepressant potential, which was described in the early studies. Here, GHB 
showed effectiveness in core effects of depression, such as fatigue, anhedonia and 
depressed mood. To complete the spectrum of the pharmacological properties of GHB, its 
distinct neuroendocrine effects have to be considered.          
 
 
Neuroendocrine effects of GHB 
 
During the past decades, strong efforts have been made to identify biological alterations in 
depression, which could serve either as diagnostic or prognostic markers or as therapeutical 
targets. Neuroendocrine, genetic and sleep parameters were investigated for their potential 
use as biomarkers of depression. In this regard, the most promising results were achieved 
for neuroendocrine and sleep measures (Kupfer, 1978; Holsboer and Ising, 2010; Steiger 
and Kimura, 2010). 
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Although not specific, neuroendocrine alterations might have a high sensitivity for depression 
(Heuser et al., 1994). A common finding during a depressive episode is a dysregulation of 
the hypothalamus-pituitary-adrenal (HPA) axis (Ising et al., 2005; Ising et al., 2007). A 
chronic hyperactivity of the HPA axis results in increased plasma concentrations of the stress 
hormones corticotropin-releasing hormone (CRH), arginine vasopressin (AVP), 
adrenocorticotropic hormone (ACTH) and cortisol. These hormones induce 
psychopathological changes such as increased anxiety, fatigue, exhaustion and memory 
impairment (Holsboer and Ising, 2010). However, morphological alterations of brain 
structures can also be detected in patients with stress-related depression. Loss of 
hippocampus volume is a prominent finding, which is hypothesized to be due to chronic 
cortisol exposure in case of HPA hyperactivity (McEwen, 2001; Pruessner et al., 2010).  
 
Antidepressants such as citalopram, venlafaxine, reboxetine and mirtazapine are known to 
exert a normalizing effect on a dysregulated HPA activity, which partially correlates with 
psychopathological improvement. It was posited, that this effect may be important for the 
antidepressant property of such agents (Schule, 2007). Moreover, neurosteroids and 
oxytocin are discussed to play a critical role in the regulation of social and sexual behaviour, 
as well as the neurobiology of depression (Scantamburlo et al., 2009; Reddy, 2010; Schule 
et al., 2010). GHB was found to interact with HPA axis activity and neurosteroidogenesis 
(Barbaccia, 2004; Nava et al., 2007) and was hypothesized to have an impact on 
oxytocinergic brain structures (McGregor et al., 2008). Considering an antidepressive 
potential of GHB, these interactions are of particular interest if one assumes GHB to be a 
model antidepressant compound with GABAergic, monoaminergic and neuroendocrine 
mechanisms of action. 
 
Neurosteroids 
Neurosteroids such as the centrally synthesized progesterone analogues allopregnanolon 
(3α,5α-THP) and allotetrahydrodeoxy-corticosterone (3α,5α-THDOC), have prosexual, 
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anxiolytic and stress reducing effects. Comparable to benzodiazepines, these effects are 
mainly due to an agonist action at GABAA receptors (Rupprecht and Holsboer, 1999; Frye et 
al., 2009). In rats, allopregnanolon reduces the reactivity to stress by inhibiting central CRH 
release. At the same time, cerebral expression of mineralocorticoid (MR) and glucocorticoid 
receptors (GR) and of AVP is reduced (Patchev et al., 1994; Patchev et al., 1996). Moreover, 
allopregnanolon showed antidepressant-like effects in mice, which was potentiated by 
serotonergic agents such as fluoxetine and fenfluramine (Khisti and Chopde, 2000; Khisti et 
al., 2000). Patients suffering from major depression and co-morbid depressive symptoms in 
posttraumatic stress disorder, show decreased plasma and CSF concentrations of 3α,5α-
THP (Romeo et al., 1998; Uzunova et al., 1998; Rasmusson et al., 2006). Fluoxetine and 
mirtazapine treatment could normalize these neurosteroid imbalances (Uzunova et al., 1998; 
Schule et al., 2006). Deficits in neurosteroidogenesis were hypothesized to play a significant 
role in the pathophysiology of depression and posttraumatic stress disorder (Rupprecht and 
Holsboer, 1999; Pinna, 2010). Synthetic neurosteroids or pharmacological agents that 
modulate neurosteroidogenesis are discussed as novel therapeutic strategies in depression 
and anxiety disorders (Schule et al., 2011). Interestingly, 3α,5α-THP and 3α,5α-THDOC are 
dose-dependently released after GHB application in rats. The time course of the elevated 
neurosteroid brain concentrations correlates with the GHB-induced sedation (Barbaccia, 
2004). Both, the sedation and the increased neurosteroidogenesis are inhibited by GABAB 
receptor antagonists (Carai et al., 2001; Barbaccia et al., 2002). It could be shown, that the 
sedative effect of GHB in rats is due to a rise of brain concentration of the neurosteroids 
3α,5α-THP and 3α,5α-THDOC (Barbaccia et al., 2005). 
 
Oxytocin 
Another hormone of primary interest for the explanation of emotional and behavioral effects 
of GHB is the “binding-hormone” oxytocin (OT), which is a peptide hormone and a functional 
antagonist of the stress hormone AVP. OT regulates social affiliation and social recognition 
in many species and modulates anxiety, mood and aggression. OT inhibits the HPA axis 
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under stress, reduces amygdala hyperactivity in depressed patients and enhances social 
behaviour (Heinrichs et al., 2003; Zak et al., 2007; Meyer-Lindenberg, 2008). However, a 
direct antidepressant effect of OT was not studied to date (Stein, 2009). It is hypothesized 
that GHB may induce its characteristic prosocial and prosexual effects due to an activation of 
brain OT systems. Social and sexual behaviour is facilitated by interactions of OT with the 
mesolimbic dopamine system (McGregor et al., 2008). GHB has a strong impact on 
dopamine release. Stimulation of OT neurons might be one of the mechanisms by which the 
drug modulates the dopaminergic tone. It could be shown that OT release is a core 
neuroendocrine feature of MDMA effects, which is correlated with the feeling of closeness, 
euphoria and loss of boundaries (Dumont et al., 2009). If this may also be the case for GHB, 
has not been studied in humans, yet. The prosocial properties of GHB are comparable to the 
ones of MDMA - without showing MDMA-related acute negative secondary effects such as 
hyperthermia, acute psychosis, panic attacks and insomnia (Karlsen et al., 2008). Moreover, 
GHB has anti-aggressive (Navarro et al., 2007; Pedraza et al., 2007) and anxiolytic 
properties (Schmidt-Mutter et al., 1998; Frawly and McMillan, 2008) and seems to be clearly 
prosexual (Degenhardt et al., 2002; Sumnall et al., 2008). An indicative for its OT-stimulating 
effects could be the former use of GHB to induce uterine contractions in childbirth 
(Geldenhuys et al., 1968). Regarding the putative role of GHB in the hormonal regulation of 
stress and depression, it is of particular interest that OT has an inhibitory effect on HPA 
activity (Uvnas-Moberg, 1998; Legros, 2001; Windle et al., 2004). Further studies are needed 
to understand the complex interactions of hormones in the regulation of affectivity and 
affective deficits and the various effects of GHB in this context. 
 
Growth hormone and the HPA axis 
In the 1980ies GHB became popular among bodybuilders because of its capacity of 
stimulating growth hormone (GH) secretion. GH secretion after intake of GHB is due to 
stimulation of both specific pituitary GHB and cerebral GABAB receptors (Vescovi and Coiro, 
2001). However, blocking of muscarinic cholinergic receptors with the anticholinergic agent 
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pirenzepine leads to a suppression of GHB-induced GH secretion in humans (Volpi et al., 
2000). This indicates an important downstream effect of GHB on the cholinergic system. The 
GH stimulating effect of GHB seems to correlate with its capacity to induce slow wave sleep 
(Van Cauter et al., 1997).  
The effects of GHB on the HPA axis were examined in several trials, but the results were 
controversial. Slow wave sleep is accompanied by a reduced HPA activity and an increase of 
GH secretion. Paradoxically, GHB induces deep sleep and seems to stimulate both cortisol 
and GH release. Under resting conditions GHB induces a stimulation of cortisol secretion in 
animals and humans (Oyama et al., 1969; Van Cauter et al., 1997; Meerlo et al., 2004). One 
case of hypercortisolism was reported following chronic illicit use of GHB (Razenberg et al., 
2007). In contrast, GHB showed a lasting suppression of withdrawal associated 
hypercortisolism in alcoholic patients (Nava et al., 2007). Moreover, previous studies showed 
a smaller activation of the HPA axis under stress after GHB application (Korolev et al., 1979; 
Malyshev et al., 1981). These data suggest that GHB might normalize a dysregulated HPA 
axis (possibly by neurosteroidogenesis), while normal HPA activity might be altered by the 
drug.  
 
 
GHB, sleep and residual symptoms of depression 
 
Major depression is associated with pronounced alterations in sleep architecture, such as 
SWS reduction, sleep fragmentation, and rapid-eye-movement (REM) sleep disinhibition 
(Kupfer, 1978; Borbely et al., 1984; Germain et al., 2004; Steiger and Kimura, 2010). 
Interestingly and as mentioned before, GHB induces slow wave sleep (SWS) in healthy 
subjects and increases both SWS and sleep efficacy with concomitant reduction of daytime 
sleepiness in patients with narcolepsy, fibromyalgia and Parkinson's disease. This effect 
leads to a marked increase in social functioning and quality of life in these patients (Pardi 
and Black, 2006; Mamelak, 2009). However, the physiological nature of GHB-induced sleep 
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is still under debate (Meerlo et al., 2004; Vienne et al., 2010). In populations, which are 
specifically sensitive to REM-sleep induction such as older healthy subjects or patients with 
affective disorders or narcolepsy, GHB acutely exerts a facilitative effect on REM sleep 
(Mamelak et al., 1977; Broughton and Mamelak, 1980; Lapierre et al., 1990). A case report 
of a markedly reduced REM latency after GHB application in a patient in remission of major 
depressive disorder, led to the idea of using GHB REM-latency induction as a biological 
marker for depression (Lapierre et al., 1989). Monoaminergic insufficiency and cholinergic 
supersensitivity was accounted for reduced REM-latency in both, depression (Belmaker and 
Agam, 2008; Dilsaver, 1986; Janowsky et al., 1972) and narcolepsy (Nishino, 2007; 
Shiromani et al., 1987). Four to six weeks of treatment with GHB normalized the altered 
REM-latency in patients with narcolepsy (Mamelak et al., 2004). Mamelak (2009) stated that 
this improvement might be explained by the capacity of GHB to recover monoaminergic and 
cholinergic dysbalance, and that this mechanism might be also effective in mood disorders. 
 
Despite scientific advances in the treatment of major depressive disorder, antidepressant first 
line agents yield only modest remission rates (Trivedi et al., 2006). One major problem is the 
presence of residual symptoms such as sleep disturbances, fatigue/daytime sleepiness and 
cognitive impairment (Kurian et al., 2009). These symptoms often precede depressive mood 
symptoms and persist after remission, exposing the patient to a higher risk for a new 
depressive episode (Judd et al., 2000). The pharmacological treatment of depression related 
sleep disorders can be especially challenging. Potent hypnotic agents such as 
benzodiazepines are limited by the risk of inducing tolerance or even addiction and sedating 
tricyclic antidepressants show an unfavourable side-effect profile (Becker, 2006; Becker and 
Sattar, 2009). Lastly, more recent and well-tolerated sedating antidepressants such as 
mirtazapine often generate hangovers and exacerbate daytime sleepiness, which is a 
disrupting symptom of depression itself (Baldwin and Papakostas, 2006). Treatment 
strategies that target fatigue and cognitive dysfunction often include psychostimulants such 
as methylphenidate, modafinil or atomoxetine. However, the tolerability of these agents 
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makes them undesirable treatment choices (Kurian et al., 2009). The almost typical patterns 
of sleep disturbances in depression, with concomitant daytime sleepiness make this 
syndrome a potential target for treatment with GHB. However, such a study has not been 
performed to date. 
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Conclusions  
 
 Depression is still conceptualized as a state of monoaminergic insufficiency and cholinergic 
supersensitivity. Neuroendocrine dysbalances, such as HPA axis hyperactivity, neurosteroid 
and growth hormone deficiency, and sleep alterations including reduced slow wave sleep 
and REM-latency are discussed as biological markers of affective disorders. Most 
antidepressant drugs exert their effects via increasing the concentration of monoamines in 
the synaptic cleft. Recent research focussed on new targets for the pharmacological 
treatment of depression, such as the GABAergic system. GHB is a GABAB and GHB 
receptor agonist with specific effects on neuroendocrine and sleep parameters. It stimulates 
neurosteroidogenesis in animals and was shown to reduce HPA hyperactivity in humans. 
Given at night, slow wave sleep and growth hormone secretion are increased. In patients 
with narcolepsy, GHB normalizes sleep disturbances and reduces daytime sleepiness and 
cataplexy. This was attributed to the capacity of the drug to normalize monoaminergic and 
cholinergic tone. Although a certain potential for the treatment of depression was already 
suspected in early studies, an explicit impetus to examine the effects of GHB in affective 
disorders was given only recently. New GABAB/GHB receptor activating compounds might be 
developed, which share GHBs beneficial effects without having the same addictive and 
properties and with a broader therapeutic dose range. Given that GHB exerts its effects on 
several strongly linked neurobiological core clinical symptoms of depression such as 
anhedonia, social withdrawal and sleep disturbances, it might also serve as a model 
compound possibly leading to novel strategies in the treatment of affective disorders. 
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